MFMaksym Fritsak

Maksym Fritsak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maksym Fritsak has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    CADS: a comprehensive anatomical dataset and segmentation for whole-body anatomy in computed tomography

    by Murong Xu, Fernando Navarro, Maksym Fritsak, Ibrahim Ethem Hamamci, Suprosanna Shit, Bastian Wittmann, Sezgin Er, Sebastian M. Christ, Ezequiel de la Rosa, Julian Deseoe, et al.

    Volumetric computed tomography (CT) segmentation supports quantitative image analysis, but most AI-based methods remain organ-specific, with fragmented models, inconsistent label definitions, and heterogeneous training and evaluation protocols. Here we present CADS, a unified data–model framework for scalable and generalizable whole-body CT segmentation. We construct a SNOMED-CT-referenced anatomical label space harmonizing heterogeneous cohorts from over 100 imaging centers, yielding complete annotations of 167 structures across 22,022 CT volumes and markedly expanding anatomical coverage and scale beyond existing resources. To complete labels on sparsely annotated CTs, we combine self-training with shape-informed quality control based on neural implicit functions, curating high-quality pseudo-labels. Trained on this resource, CADS shows robust whole-body segmentation across distribution shifts and improved performance relative to state-of-the-art approaches across 18 public datasets. We further validate it in an independent, expert-reviewed real-world oncology cohort of 2864 CTs. The curated dataset, pretrained models, and user-friendly software together provide an accessible, reproducible foundation for large-scale anatomical segmentation and computational anatomy research.

  • Open Access

    Longitudinal radiomics of liver metastases during magnetic resonance-guided radiotherapy (MRgRT)

    by Alina Paunoiu, Maksym Fritsak, Hubert Gabrys, Sebastian Christ, Matthias Guckenberger, Stephanie Tanadini-Lang, Riccardo Dal Bello

    Background and purpose: Magnetic resonance-guided radiotherapy (MRgRT) offers high-quality soft tissue contrast and treatment monitoring that can be leveraged for longitudinal radiomics analysis. We investigated treatment-related changes in MRgRT-based features during stereotactic body radiotherapy (SBRT) for liver metastases and surrounding healthy liver.Materials and methods: Features were extracted from the gross tumor volume (GTV) and five 2-cm concentric liver rings around the planning target volume (PTV) in 34 patients treated with five-fraction MRgSBRT on the ViewRay MRIdian system. Features below baseline variability and highly correlated (Spearman’s |r|>0.9) were excluded, with pre-treatment values averaged into a robust baseline. Temporal evolution, quantified using linear regression slopes, informed UMAP and HDBSCAN clustering for patient stratification, with false discovery rate-corrected Kruskal–Wallis testing identifying representative features. Correlations with GTV volume and mean cumulative liver-ring dose were evaluated.Results: Of 160 GTV features, 55 uncorrelated features were retained. Three patient groups with distinct longitudinal patterns (n=4, 10, and 20 patients) were identified. Intensity-based energy showed significant longitudinal differences across patient groups (adjusted p=0.001), weakly correlated (|r|<0.7) with volume in the two larger groups. In the innermost liver ring, 49 uncorrelated features were analyzed. Two patient groups (n=19 and 15 patients) were identified, with intensity-based energy, mean intensity, and maximum intensity showing significant longitudinal differences between the groups, weakly correlated with the mean cumulative dose.Conclusions: This longitudinal MR-based radiomics framework identified GTV- and healthy-liver-based patient groups, with distinct treatment-related feature changes. This pipeline can be extended to integrate treatment response assessment in future MRgRT radiomic studies.

  • Open Access

    Generalizing Beyond Training Data: Performance Assessment of the Best AutoPET III Model on Diverse Cancer Types

    by Maksym Fritsak, Hubert Gabrys, Maximilian Rokuss, Sebastian Christ, Nicolas Martz, Alina Paunoiu, Isabelle Opitz, Rolf A. Stahel, Martin W. Huellner, Matthias Guckenberger, et al.

    Background and Purpose Accurate image-based cancer detection and segmentation remain challenging for artificial intelligence models. Most existing solutions are optimized for specific tumor types or anatomical regions, showing limited generalizability beyond their original domains. In this study, we evaluated whether the winning model of the AutoPET III challenge, trained on metastatic datasets, could demonstrate broader applicability.Materials and MethodsThe AutoPET winning PET/CT cancer segmentation model, trained on images of lymphoma, metastatic melanoma, lung cancer, and healthy control datasets, was validated across internal and external datasets, including melanoma, lung cancer, head and neck cancer, soft tissue sarcoma, breast cancer, and healthy controls. Validation focused on detection and segmentation performance, as well as lesion-wise analyses of volume, glycolysis, and total tumor burden.ResultsModel performance varied depending on cancer type and lesion size. Overall detection rates were highest in metastatic melanoma (recall=0.84, precision=0.75). False-positive findings occurred across all datasets, predominantly in small lesions (1cc) across melanoma, lung cancer, and head and neck cancer (ICC(3,1)≥0.94). Total tumor burden estimation performed best in melanoma (ICC(3,1)=0.86). Only 29% of scans were correctly classified as negative.ConclusionsThe analyzed model demonstrated strong performance in melanoma and moderate performance in lung cancer, while performance in other tumor types was limited. The 71% misclassification rate among healthy controls represents a major limitation.

  • Navigating Scientific Progress in Radiation Oncology: Comprehensive Analysis of Clinical Trials From the Past Two Decades Using the ClinicalTrials.gov Database

    by Sebastian M. Christ, Maksym Fritsak, Gabriel Kobeissi, Philip Heesen, Siyer Roohani, Rifaquat Rahman, Ajay Aggarwal, Matthias Guckenberger

    PURPOSE: Oncology has experienced substantial growth in clinical trial activity over the past two decades, but a comprehensive evaluation of radiation oncology research is lacking. This study analyzed trends in radiation therapy trials using data from ClinicalTrials.gov. MATERIALS AND METHODS: A comprehensive analysis was conducted on 4,253 radiation oncology trials registered in the database. Key outcomes examined included trends in trial activity over time, the geographic distribution of trials, and the phases of clinical trials conducted. RESULTS: Clinical trial activity in radiation oncology has increased significantly, with 4,253 trials registered by February 2024. Digestive, CNS, and head and neck cancers accounted for 49.7% of studies. Research on oligometastasis emerged in the past decade (2.2%), while hematology trials declined (9.7%). Phase II trials dominated (51.3%), with most originating in North America (58.2%). Europe (21.2%) and Asia (25.2%) have shown increasing contributions, reflecting a global shift. Only 6% of trials received industry funding, highlighting the financial challenges in the field. CONCLUSION: These findings underscore the dynamic nature of radiation oncology research and the need to address regional disparities, advance novel technologies and drug-radiotherapy combinations through phase I and III trials, and increase industry investment.